Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

40.17 -0.62 (-1.52%)
Streaming Delayed Price Updated: 12:59 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
News headline image
Why Vera Therapeutics Stock Zoomed Higher Today ↗
The company has a fine chance of commercializing its leading investigational drug in the near future. 
Via The Motley Fool
News headline image
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Why Vera Therapeutics Stock Rocked the Market on Tuesday ↗
A competitor recently earned FDA approval, but this drug is reportedly going to be pricey. 
Via The Motley Fool
News headline image
Why Vera Therapeutics Stock Crushed it Today ↗
If all goes well, the company will have a drug on the market that could bring in billions of dollars in revenue. 
Via The Motley Fool
News headline image
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
From Vera Therapeutics
Via GlobeNewswire
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
From Vera Therapeutics
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
VERA THERAPEUTICS INC (NASDAQ:VERA) Reports Q3 2025 Earnings, Misses EPS Estimates Amid Key Clinical Progress ↗
Vera Therapeutics posts Q3 2025 financial results with a widened loss, but key clinical progress for atacicept in IgAN and an upcoming BLA submission drive investor focus. 
Via Chartmill
Topics Earnings
News headline image
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase ↗
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase 
Via The Motley Fool
News headline image
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
From Vera Therapeutics
Via GlobeNewswire
News headline image
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗
Via The Motley Fool
News headline image
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market ↗
Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment. 
Via Benzinga
News headline image
This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.